CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC).

Pourhassan says that after the first interim analysis, the DSMC requested a second one of all data after enrollment had reached 293 patients or 75% of the total patients for the trial. He says the group will continue to advance enrollment to achieve the trial’s planned 390 patients and are currently evaluating the ability to conduct an interim analysis as soon as possible.